Type | Variant | ||||
---|---|---|---|---|---|
1.0 4 APK | |||||
Size: 12.84 MB Certificate: 14edc70d58803a5ff0f3758c4a4a503478c92496 SHA1 signature: b3b449679c4e10d2b064080d5b8e58626a235e73 Architecture: universal Screen DPI: ldpi (120dpi), mdpi (160dpi), hdpi (240dpi), xhdpi (320dpi), xxhdpi (480dpi), xxxhdpi (640dpi) Device: laptop, tablet, phone | |||||
1.0 4 APKs | |||||
Size: 12.83 MB Certificate: 14edc70d58803a5ff0f3758c4a4a503478c92496 SHA1 signature: 630f961a53c7e181578bd3ff1dfd90a5675e198a Architecture: universal Screen DPI: ldpi (120dpi), mdpi (160dpi), tvdpi (213dpi), hdpi (240dpi), xhdpi (320dpi), xxhdpi (480dpi), xxxhdpi (640dpi) Device: phone |
Download Adapted01 Breast Cancer APK free
Adapted01 Breast Cancer
Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS ≤25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].
Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS ≤25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].
Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS ≤25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].
Show more
What´s new
- First Release
More info
Updated in
2021-08-23
Size
12.84 MB
Current version
1.0
Requires Android
5.0 and up
Content Rating
Everyone
Offered By
Alessandro Gaudenzi
Developer [email protected]